What is ElevateBio?
ElevateBio, founded in 2019 and headquartered in Cambridge, Massachusetts, is a pioneering company dedicated to creating and operating a portfolio of cell and gene therapy companies. It achieves this through strategic partnerships with innovative scientists and inventors, aiming to accelerate the development and commercialization of groundbreaking therapies. The company's model focuses on building and scaling biotech ventures, leveraging scientific expertise and robust operational capabilities to bring novel treatments to market. Its strategic approach positions it as a key player in the rapidly evolving landscape of regenerative medicine and advanced therapeutics.
How much funding has ElevateBio raised?
ElevateBio has raised a total of $1.2B across 4 funding rounds:
Series A
$150M
Series B
$170M
Series C
$525M
Series D
$401M
Series A (2019): $150M with participation from EcoR1 Capital, UBS Oncology Impact Fund, MPM Capital, F2 Ventures, Samsara BioCapital, and Redmile Group
Series B (2020): $170M led by EDBI, Redmile Group, The Invus Group, Vertex Ventures, MPM Capital, F2 Ventures, Surveyor Capital, Samsara BioCapital, and EcoR1 Capital
Series C (2021): $525M supported by Samsara BioCapital, Emerson Collective, ITOCHU, SoftBank Group Corp., Vertex Ventures, Surveyor Capital, Invus, Matrix Capital Management Company, Redmile Group, EDBI, EcoR1 Capital, Fidelity, MPM Capital, and F2 Ventures
Series D (2023): $401M featuring Matrix Capital Management, Woodline Partners, Invus, and Emerson Collective
Key Investors in ElevateBio
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, aiming to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation and developing new medicines.
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund, focusing on converting science into therapeutics.
Vertex Ventures
Vertex Ventures US is an early-stage venture capital firm that supports founders creating a smarter digital economy through B2B software, focusing on infrastructure and SaaS companies.
What's next for ElevateBio?
With the recent influx of capital, ElevateBio is poised for significant advancements in its pipeline and operational capacity. The substantial enterprise-level funding suggests a focus on scaling its existing portfolio companies, potentially expanding into new therapeutic areas, and further investing in research and development. This strategic investment will likely enable ElevateBio to accelerate clinical trials, enhance manufacturing capabilities, and pursue strategic acquisitions or partnerships to broaden its therapeutic reach. The company's trajectory indicates a strong commitment to becoming a leader in the cell and gene therapy space, with future growth expected to be driven by innovation and strategic market positioning.
See full ElevateBio company page
